COVID-19 Resources

As we all work to navigate the impact of COVID-19 on the health care sector and how care is delivered, ASPL wants to ensure our members have access to valuable resources to help you manage guidance being issued related to this pandemic.  If your organization has resources it would like to share, please forward the information to [email protected].

National Alliance of State Pharmacy Associations -
Bula Intelligence - Bula Blog
Faegre Drinker - Coronavirus (COVID-19) Resource Center
Hall Render - COVID-19 Resource Center
National Alliance of State Pharmacy Associations - COVID-19 State Rulings
National Association of Boards of Pharmacy - COVID-19 Resource Center
Quarles & Brady - COVID-19: Guidance for Clients



The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a nonprofit organization with the purposes of

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

July 21, 2020

Novartis reaches 3 settlements in late June and early July totaling over $1 billion

On July 1, US Attorneys in the SDNY and D. Mass. announced FCA settlements with Novartis over violations of the Anti-Kickback Statute in its promotional activities: the SDNY settlement dealt with payments to health care providers (HCPs) participating in the firm’s promotional programs; the D. Mass. Settlement arose over allegations of misfeasance in providing payments to 3 copay assistance foundations. The New York settlement provided for $591 million in FCA damages, forfeitures of $38 million, and payments of $48 million to various states. The Massachusetts settlement resulted in $51 million to resolve the claims. These settlements were announced approximately a week after the DOJ, SEC, and Novartis reached settlements under the Foreign Corrupt Practices Act for more than $346 million.

A fuller discussion of the settlements and “key takeaways” for other firms was provided by authors from Paul|Hastings. [Giampetruzzi GF, Yoon JH, González S, Mottweiler M. On the heels of significant FCPA settlements, past and present meet as Novartis reaches FCA settlements in two districts. Insights,, 2020 Jul 16;]